Limits...
Characterization of pulmonary function in Duchenne Muscular Dystrophy

View Article: PubMed Central - PubMed

ABSTRACT

Pediatr pulmonol. 2015; 50:487–494.: Decline in pulmonary function in Duchenne Muscular Dystrophy (DMD) contributes to significant morbidity and reduced longevity. Spirometry is a widely used and fairly easily performed technique to assess lung function, and in particular lung volume; however, the acceptability criteria from the American Thoracic Society (ATS) may be overly restrictive and inappropriate for patients with neuromuscular disease. We examined prospective spirometry data (Forced Vital Capacity [FVC] and peak expiratory flow [PEF]) from 60 DMD patients enrolled in a natural history cohort study (median age 10.3 years, range 5–24 years). Expiratory flow‐volume curves were examined by a pulmonologist and the data were evaluated for acceptability using ATS criteria modified based on the capabilities of patients with neuromuscular disease. Data were then analyzed for change with age, ambulation status, and glucocorticoid use. At least one acceptable study was obtained in 44 subjects (73%), and 81 of the 131 studies (62%) were acceptable. The FVC and PEF showed similar relative changes in absolute values with increasing age, i.e., an increase through 10 years, relative stabilization from 10–18 years, and then a decrease at an older age. The percent predicted, FVC and PEF showed a near linear decline of approximately 5% points/year from ages 5 to 24. Surprisingly, no difference was observed in FVC or PEF by ambulation or steroid treatment. Acceptable spirometry can be performed on DMD patients over a broad range of ages. Using modified ATS criteria, curated spirometry data, excluding technically unacceptable data, may provide a more reliable means of determining change in lung function over time. © 2015 Wiley Periodicals, Inc.

No MeSH data available.


Forced Vital Capacity [FVC], in liters (A); Peak Expiratory Flow [PEF], in liters/minute (B); percent predicted FVC (C); and percent predicted PEF (D) for patients with PFTs fulfilling the modified ATS criteria. Data are mean ± SD. N = 2–17 per data point. For reference, the horizontal lines depict 100% (solid) and 50% (dotted) of predicted FVC and PEF.
© Copyright Policy - creativeCommonsBy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4402127&req=5

ppul23172-fig-0001: Forced Vital Capacity [FVC], in liters (A); Peak Expiratory Flow [PEF], in liters/minute (B); percent predicted FVC (C); and percent predicted PEF (D) for patients with PFTs fulfilling the modified ATS criteria. Data are mean ± SD. N = 2–17 per data point. For reference, the horizontal lines depict 100% (solid) and 50% (dotted) of predicted FVC and PEF.

Mentions: In order to maximize data integrity, modified ATS guidelines for acceptability of spirometry (Table 1) were used to determine acceptability. From the 131 PFTs collected across all age groups, 81 PFTs (61.8%) from 44 patients were considered acceptable. The 6–16 year‐old subjects performed acceptable spirometry 63.7% of the time, compared to only 55.2% for the subjects over 16 years of age. Both FVC (L) and PEF (L/min) changed in three phases with increasing age. Up to approximately 10 years of age, subjects showed a nearly linear increase in FVC (Fig. 1A) and PEF (Fig. 1B), followed by a period of relative stabilization through 18 years, after which there was a rapid decline. However, FVC% (Fig. 1C) and PEF% (Fig. 1D) declined almost linearly from the 6–8 years of age cohort through the 20–22 years of age cohort.


Characterization of pulmonary function in Duchenne Muscular Dystrophy
Forced Vital Capacity [FVC], in liters (A); Peak Expiratory Flow [PEF], in liters/minute (B); percent predicted FVC (C); and percent predicted PEF (D) for patients with PFTs fulfilling the modified ATS criteria. Data are mean ± SD. N = 2–17 per data point. For reference, the horizontal lines depict 100% (solid) and 50% (dotted) of predicted FVC and PEF.
© Copyright Policy - creativeCommonsBy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4402127&req=5

ppul23172-fig-0001: Forced Vital Capacity [FVC], in liters (A); Peak Expiratory Flow [PEF], in liters/minute (B); percent predicted FVC (C); and percent predicted PEF (D) for patients with PFTs fulfilling the modified ATS criteria. Data are mean ± SD. N = 2–17 per data point. For reference, the horizontal lines depict 100% (solid) and 50% (dotted) of predicted FVC and PEF.
Mentions: In order to maximize data integrity, modified ATS guidelines for acceptability of spirometry (Table 1) were used to determine acceptability. From the 131 PFTs collected across all age groups, 81 PFTs (61.8%) from 44 patients were considered acceptable. The 6–16 year‐old subjects performed acceptable spirometry 63.7% of the time, compared to only 55.2% for the subjects over 16 years of age. Both FVC (L) and PEF (L/min) changed in three phases with increasing age. Up to approximately 10 years of age, subjects showed a nearly linear increase in FVC (Fig. 1A) and PEF (Fig. 1B), followed by a period of relative stabilization through 18 years, after which there was a rapid decline. However, FVC% (Fig. 1C) and PEF% (Fig. 1D) declined almost linearly from the 6–8 years of age cohort through the 20–22 years of age cohort.

View Article: PubMed Central - PubMed

ABSTRACT

Pediatr pulmonol. 2015; 50:487–494.: Decline in pulmonary function in Duchenne Muscular Dystrophy (DMD) contributes to significant morbidity and reduced longevity. Spirometry is a widely used and fairly easily performed technique to assess lung function, and in particular lung volume; however, the acceptability criteria from the American Thoracic Society (ATS) may be overly restrictive and inappropriate for patients with neuromuscular disease. We examined prospective spirometry data (Forced Vital Capacity [FVC] and peak expiratory flow [PEF]) from 60 DMD patients enrolled in a natural history cohort study (median age 10.3 years, range 5–24 years). Expiratory flow‐volume curves were examined by a pulmonologist and the data were evaluated for acceptability using ATS criteria modified based on the capabilities of patients with neuromuscular disease. Data were then analyzed for change with age, ambulation status, and glucocorticoid use. At least one acceptable study was obtained in 44 subjects (73%), and 81 of the 131 studies (62%) were acceptable. The FVC and PEF showed similar relative changes in absolute values with increasing age, i.e., an increase through 10 years, relative stabilization from 10–18 years, and then a decrease at an older age. The percent predicted, FVC and PEF showed a near linear decline of approximately 5% points/year from ages 5 to 24. Surprisingly, no difference was observed in FVC or PEF by ambulation or steroid treatment. Acceptable spirometry can be performed on DMD patients over a broad range of ages. Using modified ATS criteria, curated spirometry data, excluding technically unacceptable data, may provide a more reliable means of determining change in lung function over time. © 2015 Wiley Periodicals, Inc.

No MeSH data available.